An open-label, pilot study to compare the safety and immunogenicity of an alternate dosing schedule (2-5 weeks, 2, and 4 months) for pentavalent rotavirus vaccine (RotaTeq) to the standard recommended schedule (2, 4 and 6 months).
Research Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Merck Sharp & Dohme
Start Date
August 1, 2013
End Date
June 30, 2021
Administered By
Duke Human Vaccine Institute
Awarded By
Merck Sharp & Dohme
Start Date
August 1, 2013
End Date
June 30, 2021